我们的网站为什么显示成这样?

可能因为您的浏览器不支持样式,您可以更新您的浏览器到最新版本,以获取对此功能的支持,访问下面的网站,获取关于浏览器的信息:

|本期目录/Table of Contents|

κ-阿片受体激动剂U50 488H的季胺化改造

《心脏杂志》[ISSN:1009-7236/CN:61-1268/R]

期数:
2013年第2期
页码:
185-189
栏目:
基础研究
出版日期:
2013-04-25

文章信息/Info

Title:
Structural transformation of κ-opioid receptor agonist (U50 488H) to quaternary ammonium salt
作者:
王倩梅贾 敏冯 娜张淑苗李 娟樊 荣王跃民裴建明
(第四军医大学基础部生理学教研室,陕西 西安 710032)
Author(s):
WANG Qian-mei JIA Min FENG Na ZHANG Shu-miao LI Juan FAN Rong WANG Yue-min PEI Jian-ming
(Department of Physiology, Fourth Military Medical University, Xi’an 710032, Shaanxi, China)
关键词:
U50 488H季胺化成瘾
Keywords:
U50 488H quaternary ammonium salt addiction
分类号:
R541.7
DOI:
-
文献标识码:
A
摘要:
目的:通过对κ-阿片受体激动剂U50 488H的结构进行季胺化改造,使其不能通过血脑屏障,从而消除可能存在的成瘾和依赖性。方法: 对U50 488H进行季胺化改造,使用质谱法确认该季胺化产物,使用高效液相色谱法对比测定U50 488H及改造后的季胺化U50 488H在血清和脑中的浓度。结果: 季胺化后的U50 488H呈淡黄色粉末样,经质谱分析,确认所得产物为U50 488H的碘甲烷季铵盐C20H29Cl2IN2O。后者溶解度较U50 488H明显增大。分别静脉注射U50 488H或季胺化U50 488H后,经色谱分析在血清中均可检测到所注射的药物;而在脑组织液中可以检测到U50 488H,却检测不到季胺化U50 488H。结论: 成功改造获得一种新的化合物季胺化U50 488H,该物质不能通过血脑屏障,可以避免因U50 488H通过血液循环进入脑组织引起的成瘾和依赖性。
Abstract:
AIM:To reduce the potential addiction of U50 488H, a κ-opioid receptor agonist, by structurally transforming it to its quaternary ammonium salt incapable of going through the blood-brain barrier. METHODS: U50 488H was transformed to its quaternary ammonium salt, which was identified with mass spectrometry. The concentrations of U50 488H and its quaternary ammonium salt in serum and brain tissue were determined by chromatography. RESULTS: The quaternary ammonium salt of U50 488H was a faint yellow powder and mass spectrometry proved it to be C20H29Cl2IN2O, with remarkably increased solubility than U50 488H. Chromatography detected U50 488H in both serum and brain tissue fluid of the rats after i.v. injection. However, quaternary ammonium salt of U50 488H was detected only in serum and not in brain tissue. CONCLUSION: The structural transformation of U50 488H to its quaternary ammonium salt incapable of going through the blood-brain barrier reduces the potential addiction of U50 488H.

参考文献/References

[1]陈 迈,贾国良,裴建明,等.KATP通道介导了刺激κ阿片受体诱导的延迟性心脏保护效应[J].第四军医大学学报, 2003,24(16):1460-1462.
[2]张 鹏,朱运龙,王跃民,等.κ阿片受体选择性激动剂U50488H对心肌梗死大鼠血管紧张素Ⅱ、内皮素和一氧化氮的影响[J].中国临床康复,2006,10(22):77-79.
[3]Fan R,Zhang P,Ye MX,et al.Myocardial apoptosis and infarction after ischemia/reperfusion are attenuated by kappa-opioid receptor agonist[J].Arch Med Res,2009,40(4):227-234.
[4]王伟光,张权宇,曹钰琨,等.κ阿片受体可通过抑制β肾上腺素受体进而调节心肌细胞Cx43发挥抗缺血/再灌注性心律失常[J].中国药理学通报, 2010,26(4):471-476.
[5]张 伟,王洪新,吴国强,等.κ阿片激动对血管紧张素Ⅱ诱导心肌肥大的抑制作用[J].辽宁医学院学报,2009,30(2))122-124.
[6]Chen M,Zhou JJ,Kam KW,et al.Roles of KATP channels in delayed cardioprotection and intracellular Ca2+ in the rat heart as revealed by κ-opioid receptor stimulation with U50,488H[J].Br J Pharmacol,2003,140(4):750-758.
[7]魏保真,肖 安,毕辉,等.U50488H对缺血-再灌注大鼠心肌的直接保护作用[J].医学研究生学报,2006,19(2):136-138,142.
[8]沈敬山,刘东祥,蒋华良,等.非肽类阿片Kappa受体激动剂的研究现状[J].药学进展,1998,22(4):193-199.

备注/Memo

备注/Memo:
收稿日期:2012-09-25.基金项目:国家科技重大专项子课题资助(2009ZX09301-009-BD11);国家自然科学基金项目资助(81270402,30971060) 通讯作者:裴建明,教授,主要从事心脏内分泌研究 Email:jmpei8@fummu.edu.cn 作者简介:王倩梅,硕士生 Email:shenlanqian@126.com 共同第一作者:贾敏,助教,硕士 Email:108016154@qq.com
更新日期/Last Update: 2013-04-28